Thursday, May 13, 2010 7:01:22 AM
http://www.harbingerresearch.com/data/CNBI%20Harbinger%20Research%20Report%20May%2011%202010_57.pdf
China Baicaotang Medicine (CNBI – OTC:BB)
Compelling Valuation and Solid Growth. Vertically-
Integrated Pharma Co. Trades at Just 4.9x our 2010 EPS
Estimate. Low Downside Risk and Strong Upside Potential.
Strong
Buy
Conclusion
China Baicaotang is already a successful, well-established pharmaceutical manufacturer, wholesaler, and retailer
in the Guangxi province of China. The Company has recently gained access to significant growth capital, and is
expected to gain even more in the near future, allowing it to invest in next-generation infrastructure and more
aggressive expansion across all of its business lines. We believe that as this process progresses, the Company
will strengthen its competitive advantages in the Guangxi markets, and will likely experience rising gross and
net margins. This will almost certainly lead to multiple expansion from current “fair value” levels of 10x – 15x
forward earnings, and the Company currently trades at just 4.9x our 2010 EPS estimate of $0.67. Therefore we
rate the shares of CNBI a Strong Buy, and set our 12-month price target at $6.70 per share.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM